|
See related Fludarabin Ebewe inj information |
|
|
|
Manufacturer |
Sandoz |
|
Distributor |
Hong Kong: Zuellig/Macau: Firma Vai Hong |
|
Contents |
Fludarabine phosphate |
|
Indications |
Chronic lymphocytic leukemia (CLL) of B-cell type w/ sufficient bone marrow function. 1st- or 2nd-line treatment of sufficient bone marrow function. 1st-line treatment in later stages (RaI III/IV, Binet C) or in earlier stages if disease-related symptoms make treatment desirable. |
|
Dosage |
Adult 25 mg/m2/day IV for 5 days every 28 days. |
|
Contraindications |
Renal impairment & CrCl <30 mL/min; decompensated haemolytic anaemia. Pregnancy & lactation. |
|
Special Precautions |
Monitor signs of neurological side effects, haematological & non-haematological toxicity or autoimmune haemolytic anaemia. Discontinue in case of haemolysis. Childn. |
|
Adverse Drug Reactions |
Myelosuppression (neutropaenia, thrombocytopaenia, anaemia), pneumonia, fever, nausea, vomiting & diarrhoea.
View ADR Monitoring Form |
|
Drug Interactions |
Combination w/ pentostatin is not recommended. Efficacy may be reduced by dipyridamole & other inhibitors of adenosine uptake.
View more drug interactions with Fludarabin Ebewe |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
ATC Classification |
L01BB05 - fludarabine ; Belongs to the class of antimetabolites, purine analogues. Used in the treatment of cancer. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Fludarabin Ebewe injection |
|
Fludarabin Ebewe 50 mg/2 mL x 1's |
|
|
|
Manufacturer: |
Sandoz |
|
Distributor: |
Hong Kong: Zuellig
Macau: Firma Vai Hong |
|
|
|
|
